Pre-myeloid Cancer and Bone Marrow Failure Clinic Study


About this study

The purpose of this study is to test a new technology called Next Generation Sequencing (NGS) that may help identify this risk associated with precursor conditions and the likelihood that they will change into overt blood and bone marrow cancers. NGS is a procedure that looks at relevant cancer associated genes and what they do.

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. If you need assistance understanding the eligibility criteria, please contact the study team.

Inclusion Criteria:

Patients with:

  • Idiopathic cytopenias of unclear significance (ICUS)
  • Clonal hematopoiesis of indeterminate significance (CHIP)
  • Age related clonal hematopoiesis (ARCH)
  • Clonal cytopenias of unclear significance (CCUS)
  • Marrow failure syndromes with myeloid malignancy predisposition- telomere dysfunction, chromosomal breakage disorders, etc.
  • Germ line inherited syndromes with risk for malignant transformation
  • Low Risk Myelodysplastic Syndromes (MDS)

Exclusion Criteria:

  • Patients who are unable to understand and sign the Informed Consent Form

Participating Mayo Clinic locations

Study statuses change often. Please contact us for help.

Mayo Clinic Location Status Contact

Rochester, Minn.

Mayo Clinic principal investigator

Mrinal Patnaik, M.B.B.S.

Open for enrollment

Contact information:

Gillian Currie

(507) 266-3223

More information


Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available


Mayo Clinic Footer